Solazyme Inc. (TVIA) Shares Down 3.5%
Solazyme Inc. (NASDAQ:TVIA)’s share price traded down 3.5% on Friday . The stock traded as low as $2.48 and last traded at $2.48, with a volume of 61,302 shares changing hands. The stock had previously closed at $2.57.
The stock’s market cap is $210.63 million. The firm’s 50-day moving average is $2.40 and its 200 day moving average is $2.06.
Solazyme (NASDAQ:TVIA) last announced its quarterly earnings data on Wednesday, May 4th. The company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.02. During the same period in the previous year, the business earned ($0.37) earnings per share. The company earned $10.90 million during the quarter, compared to analysts’ expectations of $11.94 million. The business’s revenue for the quarter was down 13.5% compared to the same quarter last year. On average, analysts forecast that Solazyme Inc. will post ($1.12) EPS for the current fiscal year.
In related news, CFO Tyler Painter sold 12,500 shares of the stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $2.67, for a total value of $33,375.00. Following the completion of the transaction, the chief financial officer now directly owns 400,337 shares of the company’s stock, valued at approximately $1,068,899.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Solazyme, Inc creates renewable oils and bioproducts. The Company’s technology uses microalgae in an industrial fermentation process to transform a range of plant-based sugars into triglyceride oils and other bioproducts. The Company offers Algenist, a skin and personal care product available at Sephora SA and its affiliates, QVC, Inc, SpaceNK Limited, select Nordstrom stores and ULTA Beauty.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.